1stOncology™: Cancer Intelligence Service – Page 8783 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5

On April 21, 2021 Clovis Oncology, Inc. (NASDAQ: CLVS) reported that its first quarter 2021 financial results on Wednesday, May 5, 2021, before the open of the US financial markets (Press release, Clovis Oncology, APR 21, 2021, View Source [SID1234578300]). Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.

Dial-in numbers for the conference call are as follows: US participants 877.698.7048 International participants 647.689.5448, conference ID: 3219208.

Biovaxys Assigned BVAXF By Finra As New Us OTC Trading Symbol

On April 21, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, reported that effective today it has been assigned a new US OTC trading symbol of BVAXF (Press release, BioVaxys Technology, APR 21, 2021, View Source [SID1234578298]). This replaces the prior US OTC trading symbol of LMNGF.

BioVaxys has also applied for a OTCQB listing and anticipates approval in the upcoming weeks. The OTCQB is the mid-tier OTC equity market, which lists primarily early-stage and developing companies in the U.S. and international markets. OTCQB companies must meet certain minimum reporting standards, pass a bid test, and undergo annual verification.

Vaccibody 2020 Annual Report

On April 21, 2021 Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported that the Board of Directors has approved the Company’s financial statements for 2020 (Press release, Vaccibody, APR 21, 2021, View Source [SID1234578297]).

The Company’s annual accounts for the financial year 2020, including the financial statements and annual report, are together with the auditor’s report attached to this announcement. Vaccibody’s annual report 2020 contains the first annual accounts where the financial statements have been prepared in accordance with IFRS (International Financial Reporting Standards). The financial statements are presented in United States dollar (USD). The annual report 2020 is also available at the Company’s website, View Source

Nissan Chemical and Modulus Discovery Jointly Announce Signing of Strategic Drug Discovery Collaboration Agreement

On April 21, 2021 Nissan Chemical Corporation (Head Office: Chuo-ku, Tokyo Japan; President: Shinsuke Yagi, "Nissan Chemical"), and Modulus Discovery, Inc. (Head Office: Chiyoda-ku, Tokyo Japan; CEO: S. Roy Kimura, Ph.D., "Modulus"), an early stage global biopharmaceutical company, reported the signing of a strategic drug discovery collaboration agreement (Press release, Modulus Discovery, APR 21, 2021, View Source [SID1234578296]). Under this agreement, the companies will collaboratively accelerate the development of novel small molecule drug candidates derived from Modulus’ pipeline of R&D programs leveraging each party’s drug discovery platform and expertise.

Nissan Chemical has been developing novel medicines through proprietary drug discovery research and drug substance development functions, and has built a track record of multiple drug candidate out-licensing deals and market approvals of innovative medicines. Modulus is a preclinical-stage technology-driven drug discovery firm leveraging its cutting-edge computational technology, accumulated disease biology insights, and a networked operational platform that enables accelerated and efficient identification of small molecule drug candidates. Modulus’ proprietary pipeline of programs are focused on chronic inflammatory diseases, oncology, immune disorders, and rare genetic conditions.

This strategic collaboration aims to accelerate several of Modulus’ late-stage discovery programs toward entry into clinical trials through Nissan Chemical’s technology and know-how on drug substance development and manufacturing and sharing of development costs. Nissan Chemical will receive a portion of the profits that Modulus obtains from future licensing deals for these programs.

F. Hoffmann-La Roche Announces First Quarter Sales 2021

On April 21, 2021 F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan reported its first quarter sales 2021 (January 1 – March 31, 2021) (Press release, Chugai, APR 21, 2021, View Source [SID1234578294]).

Roche owns 59.89% of Chugai’s outstanding shares (61.16% of the total number of shares issued excluding treasury stock) as of the end of March 2021.

Its press release and presentation materials can be found on its website (View Source).
Chugai’s performance for the period of January 1 to March 31, 2021 is included in the announced Roche Group’s results.